Imeglimin

Imeglimin
Clinical data
Trade names	Twymeeg
ATC code	A10BX15 (WHO) ;
Legal status
Legal status	Rx-only in Japan;
Identifiers
	IUPAC name (2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine;
CAS Number	775351-65-0;
PubChem CID	24812808;
ChemSpider	26232690;
UNII	UU226QGU97;
CompTox Dashboard (EPA)	DTXSID50228237 ;
Chemical and physical data
Formula	C6H13N5
Molar mass	155.205 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1NC(=NC(=N1)N)N(C)C;
	InChI InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1; Key:GFICWFZTBXUVIG-SCSAIBSYSA-N;

Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication.^[1]^[2] It was approved for use in Japan in June 2021.^[3]

Trade namesTwymeeg

ATC code

A10BX15 (WHO)

Legal status

Rx-only in Japan

CAS Number

775351-65-0

Quick facts Clinical data, Trade names ...

Close

It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It is the first approved drug of this class of anti-diabetic medication.

[1]

[2]

[3]

Imeglimin

References

Related Articles